Office of Professional Education

A free CME live webinar

 

Dates and Times:

  • Tuesday, April 6, 2021 – 5:00 pm to 6:15 pm MT 
    (Begins at 7:00 pm ET, 6:00 pm CT, and 4:00 pm PT)

  • Tuesday, April 13, 2021 – 10:00 am to 11:15 am MT 
    (Begins at 12:00 pm ET, 11:00 am CT, and 9:00 am PT)

 

► Register Now!


Target Audience:

Allergists, otolaryngologists (ENT), rhinologists, primary care/family medicine/internal medicine physicians, and advanced practice providers who diagnose and treat allergic and pulmonary diseases.

 

Learning Objectives:

Upon completion of this activity, the participant will be better able to:

  1. Describe clinical features and key concepts in the pathophysiology and immunology of CRSwNP.
  2. Evaluate strategies for longitudinal management using a multidisciplinary approach.
  3. Discuss current and emerging therapies and treatment selection based on patient inflammatory phenotype, comorbidities and other individual factors. 

 

Program Faculty:

Daniel Beswick, MD
Assistant Professor-in-Residence
University of California Los Angeles
Los Angeles, CA
Adjunct Assistant Professor
National Jewish Health
Denver, CO

 
Eileen Wang, MD, MPH
Assistant Professor
Division of Allergy & Clinical Immunology
Department of Medicine
National Jewish Health
Denver, CO

 

Contact:

For questions, please email the Office of Professional Education at National Jewish Health proed@njhealth.org or call 303.398.1000 or 800.844.2305. To register, please click here.


Accreditation and Designation Statements:

Physicians:  National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

National Jewish Health designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 
 

Support:

This educational activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.